Compare GPCR & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPCR | PHAR |
|---|---|---|
| Founded | 2016 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2023 | N/A |
| Metric | GPCR | PHAR |
|---|---|---|
| Price | $68.72 | $18.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $97.90 | $38.00 |
| AVG Volume (30 Days) | ★ 1.2M | 28.7K |
| Earning Date | 02-26-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | N/A | ★ $362,274,000.00 |
| Revenue This Year | N/A | $25.19 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | ★ N/A | $3,363.09 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $13.22 | $7.50 |
| 52 Week High | $94.90 | $18.82 |
| Indicator | GPCR | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 64.14 | 61.38 |
| Support Level | $61.99 | $16.55 |
| Resistance Level | $70.40 | $17.37 |
| Average True Range (ATR) | 4.03 | 0.73 |
| MACD | -1.08 | 0.05 |
| Stochastic Oscillator | 76.21 | 92.27 |
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.